Bringing you the latest insights and news on all things Ventures

Funding updates
July 01st 2024

Backing Fertifa: the transformative reproductive healthcare solution for employers

Read Time - 3 mins

Fertifa is a tech-enabled reproductive healthcare provider helping employers support their employees going through reproductive health journeys. Fertifa fills a gap between the current offering of the private medical insurance market and the public health system.

Fertility is a largely underserved care need, people are increasingly considering having children later, and we saw in Fertifa the opportunity to fill some of this gap in a growing market need.

Notable market trends within the fertility space:

  • Demographics —the need for fertility-related healthcare is directly linked with the growing age at which the population starts building a family. Demographics show us a clear direction — couples are forming families later and later.
  • An employer’s problem — female and male fertility, menopause and broader reproductive health topics are increasingly impacting the workplace. Whether purely from a drop in productivity, the need for time off, or from a growing pressure around workplace policies to incorporate some reproductive health support. Reproductive health has become part of the employer benefits agenda. In the US, for instance, studies show that for large employers (>20,000 employees), only 23% of employers do not cover any form of reproductive health support.
  • Clearly a private health problem — as there is growing pressure across public health systems in Europe, it has become clear reproductive healthcare has dropped outside of the focus areas — there’s simply larger urgency in other healthcare areas. The UK NHS serves only very specific conditions when it comes to fertility treatments, leaving many behind. Even with such strict criteria, the UK NHS fertility treatment waitlists range between 24 and 54 weeks across the UK, placing these waitlists at the top end of the NHS waitlist ranking!
  • US precedents highly transferable to Europe — we are seeing tech-enabled fertility clinics gaining huge momentum in the US through innovative go-to-market strategies in the fertility space, and the great use of technology. Players like Maven Clinic (unicorn) and Carrot (raised >$100mn) are showing traction with an employee-focused offering for reproductive health. We saw in the European reproductive health space the most similarities between the European and American health systems— (i) reproductive health remains highly underserved by the public system, (ii) there is patient willingness to spend privately (without clear insurance cover), (iii) there is increasing interest from employers to support employees on their reproductive health journeys.

Where Fertifa comes in

Fertifa has built a tech-enabled solution to fill this gap in the reproductive health market in a tech-enabled scalable way, whilst distributing it through an innovative go-to-market strategy in Europe: selling their product and services to employers. Fertifa was founded in 2019 to provide impartial advice and wellbeing support to as many individuals as possible so they could make the best decisions for their unique and individual circumstances.

Fertifa has come across as the player in the market with the strongest clinical focus, whilst covering the broadest range of conditions. On top of its clinical support, Fertifa also has a tool to help employers manage fertility benefits plans: some companies offer employees reproductive health benefits (e.g. fertility vouchers, reimbursements) that require an unbiased 3rd party management tool to validate employee requests and claims. This has been a problem for large employers which Fertifa has been able to demonstrate a clear ROI.

The team at Fertifa has been able to demonstrate an impressive ability to execute and distribute its solution, whilst demonstrating a true passion for the health outcomes the business is creating. The perfect combination of performance and passion that motivates us at Triple Point as early stage investors.